[{"Assets_0_Q3_USD":370356000.0,"CommonStockSharesOutstanding_0_Q3_shares":146457009.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-58798000.0,"NetIncomeLoss_1_Q3_USD":-25015000.0,"NetIncomeLoss_3_Q3_USD":-37843000.0,"StockholdersEquity_0_Q3_USD":245353000.0,"Ticker":"HALO","CIK":"1159036","name":"HALOZYME THERAPEUTICS, INC.","OfficialName":"Halozyme Therapeutics Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"5856719603.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20191112"}]